REPL
Replimune Group, Inc.
NASDAQ · Healthcare · Biotechnology · US
$13.07
+1.55%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$13.05
From 52W high−18.21%
Volume2.07M
Market cap$1.23B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$13.05
From 52W high
−18.21%
Volume
2.07M
Market cap
$1.23B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.9x
P/E (TTM)
—
RSI (14)
44.0
MomentumView details →
1D Return
+1.55%
YTD Return
+34.42%
SummaryUpdated Jun 1, 2026
Replimune Group, Inc. (NASDAQ:REPL) is a clinical-stage biotechnology company founded in 2015 and headquartered in Woburn, Massachusetts. The company went public in July 2018 and specializes in developing oncolytic immuno-gene therapies, a cutting-edge approach to cancer treatment that uses genetically modified viruses to selectively target and destroy cancer cells while simultaneously activating the patient's immune system. Replimune is currently preparing for the potential commercial launch of its lead product candidate RP1, which has received breakthrough therapy designation from the FDA and has a Prescription Drug User Fee Act (PDUFA) date of July 22, 2025.
Similar companies
Latest newsMore news →
A class action was filed on behalf of investors who purchased Replimune Group, Inc. (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026, with a lead plaintiff deadline of October 5, 2026.1d agoReplimune Group announced the appointment of Michelle DiNapoli as Chief Commercial Officer.37d agoReplimune Group reported a net loss of $69.8 million for Q1 2027, compared to a net loss of $86.7 million in Q1 2026, with diluted EPS of -$0.72.38d ago